Kymera Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KYMR | GLUE | NRIX | CCCC | 688382.SS | 2162.HK | |
|---|---|---|---|---|---|---|
| Market cap | 11.63B | 923.09M | 1.74B | 383.84M | 8.38B | 20.67B |
| P/E (TTM) | — | — | 6.6 | — | — | 23.8 |
| Forward P/E | -27.1 | -5.9 | -12.5 | -3.4 | -43.8 | 206.8 |
| Price/book | 7.2 | 1.9 | 1.8 | 1.6 | 6.6 | 4.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +123.36% | −16.83% | +27.40% | +31.09% | −48.70% | +8.65% |
| Today | +7.21% | +3.94% | −38.23% | −2.80% | +4.33% | +2.48% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KYMR news ›Kailera Therapeutics (NASDAQ:KLRA) Issues Quarterly Earnings Results
Posted by Mitch Edgeman on Nov 4th, 2026 Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus…
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late…
Kyverna Therapeutics, Inc. (KYTX) – What Are Analysts Saying About This Stock?
Posted by Danessa Lincoln on Nov 4th, 2026 Read Our Latest Report on KYTX Shares of KYTX stock opened at $5.16 on Wednesday. The company has a current ratio of 9.06, a quick ratio of 9.06 and a debt-to-equity ratio of 0.15. Kyverna…
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High on Analyst Upgrade
Posted by Danessa Lincoln on Nov 3rd, 2026 Check Out Our Latest Stock Report on KYMR The firm’s 50-day moving average price is $115.08 and its 200 day moving average price is $96.61. The firm has a market cap of $10.97 billion, a P/E ratio…
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in…
Kymera Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-02. The following slide deck was published by Kymera Therapeutics, Inc. The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-10-29 Earnings Summary
Kailera Therapeutics to Participate in November Investor Conferences
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Shopify Sustains Rapid Growth with Revenue Up 32% and Free Cash Flow Margin of 22% Robo.ai Subsidiary Neurovia AI Highlights…
Karyopharm Therapeutics Inc. (KPTI) Files Chapter 11, Agrees to Ayrmid Merger
TradingView Karyopharm Therapeutics Inc. (KPTI) Files Chapter 11, Agrees to Ayrmid Merger Karyopharm filed voluntary Chapter 11 petitions and agreed to merge with Ayrmid through a court-supervised sale process, with Ayrmi
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
Nov 02, 2026, 07:10 ET – The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value…
Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Lowered by Wall Street Zen
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports. Check Out Our…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com9
- seekingalpha.com7
- marketbeat.com5
- marketscreener.com5
- defenseworld.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 35 articles, not a forecast.